Norfloxacin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Norfloxacin
- Pharmacist Assessment Report
- Norfloxacin: Hyperamylasemia
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Other Predicted Indications (for Reference)
- Conclusion and Next Steps
- Disclaimer
Norfloxacin: Hyperamylasemia
One-Sentence Summary
Norfloxacin is a fluoroquinolone antibiotic, with relations recorded in the knowledge graph for infections such as urinary tract infection, typhoid fever, dysentery and bacterial pneumonia. The TxGNN model (deep learning) predicts it may be effective for hyperamylasemia, but this is a model prediction only. There are 0 clinical trials and 0 publications supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Hyperamylasemia |
| TxGNN Prediction Score | 0.9970 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Number of approvals | At least 20 licences (the list may be partial) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general knowledge, norfloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV. Its relations recorded in the knowledge graph are bacterial infections of the urinary, respiratory and gastrointestinal tracts.
Hyperamylasemia is a laboratory finding of raised serum amylase, with causes such as pancreatic, salivary or renal disease. No plausible mechanism links bacterial enzyme inhibition to amylase regulation. The high score (rank 5654 among model predictions) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence, and is not supported by any trial or publication. The prediction should be treated as a computational hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for hyperamylasemia.
India Market Information
The list below shows 5 of at least 20 valid licences recorded. The list may be partial, and no licence in the data includes approved indication text.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 153214 | Norspan 400mg Tablet | Strip of 10 tablets | Not stated in the records |
| 172439 | Osoflox 400mg Tablet | Strip of 10 tablets | Not stated in the records |
| 222889 | Tamflox 400mg Tablet | Strip of 10 tablets | Not stated in the records |
| 157488 | Norflin 400mg Tablet | Strip of 10 tablets | Not stated in the records |
| 106769 | Hiflox 400mg Tablet | Strip of 10 tablets | Not stated in the records |
Other records are listed as combination-type products, such as norfloxacin with tinidazole, but they are not used here to describe the single-ingredient drug.
Safety Considerations
- Relations recorded in the knowledge graph (not label text): The knowledge graph links norfloxacin to contraindication relations with long QT syndrome, torsades de pointes, epilepsy, liver disease and liver failure, kidney disease, tendinitis, peripheral neuropathy, rhabdomyolysis, diabetes mellitus, diabetic ketoacidosis, thrombocytopenia, psychotic disorders and potassium deficiency, among others.
- Drug Interactions: 299 interactions are recorded. Major-level examples include hydrocortisone, dexamethasone, betamethasone, triamcinolone, bupropion and chlorpropamide. Moderate-level examples include metformin, pioglitazone, acarbose, loperamide, famotidine, aspirin and calcium or potassium salts.
Please also refer to the package insert for label warnings and contraindications.
Other Predicted Indications (for Reference)
| Rank | Predicted Disease | Score | Evidence Level | Note |
|---|---|---|---|---|
| 2 | Polyclonal hyperviscosity syndrome | 0.9970 | L5 | No mechanism or evidence |
| 3 | Congenital analbuminemia | 0.9967 | L5 | Genetic albumin disorder, no rationale |
| 4 | Blood group incompatibility | 0.9955 | L5 | No evidence |
| 5 | Punctate epithelial keratoconjunctivitis | 0.9954 | L5 | Retrieved papers concern microsporidial infection and do not study norfloxacin |
| 10 | Septicemic plague | 0.9937 | L5 | Only animal or in vitro studies on other fluoroquinolone aspects, not norfloxacin in human plague |
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for hyperamylasemia rests only on the model score. There are no trials or publications, and no plausible mechanism. The evidence level is L5. Among other predictions, only septicemic plague has a class-level antibacterial rationale, but the retrieved studies do not directly study norfloxacin in that disease. Other fluoroquinolones are better-supported candidates there.
To proceed, the following is needed:
- Mechanism of action data and a mechanistic hypothesis linking norfloxacin to amylase handling
- A literature and trial search that directly addresses hyperamylasemia
- Package insert warnings and contraindications from the local regulator for safety screening
- Review of the knowledge-graph contraindication relations (QT prolongation, neuropathy, tendon and liver disorders) against any proposed patient population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.